Anti-Infective Vaccines Market By Technology (Conjugate Vaccines, Recombinant Vaccines, Inactivated and Subunit Vaccines), Type (Inactivated Vaccines, Conjugate Vaccines), Application (Bacterial Diseases, Viral Diseases), Route of Administration (Intramuscular & Subcutaneous, Oral), End-User (Pediat
Published on: 2024-08-06 | No of Pages : 320 | Industry : latest updates trending Report
Publisher : MIR | Format : PDF&Excel
Anti-Infective Vaccines Market By Technology (Conjugate Vaccines, Recombinant Vaccines, Inactivated and Subunit Vaccines), Type (Inactivated Vaccines, Conjugate Vaccines), Application (Bacterial Diseases, Viral Diseases), Route of Administration (Intramuscular & Subcutaneous, Oral), End-User (Pediat
Anti-Infective Vaccines Market Valuation – 2024-2031
Rising dement for Anti-Infective Vaccines Market is expanding at a faster pace with high growth rates of infectious diseases over the last few years. Thus, the market size is expected to surpass USD 74.80 Billion valued in 2024 to reached a valuation of around USD 91.85 Billion by 2031.
The new research study analyzes industry trends, pricing, patents, conference and webinar materials, major stakeholders, and market purchasing behavior. Global vaccine income (excluding COVID-19 vaccines) is predicted to be about at a CAGR of 2.2% from 2024-2031.
Anti-Infective Vaccines MarketDefinition/ Overview
Anti-infective vaccines are immunizations designed to protect individuals against infectious diseases caused by various pathogens, including bacteria, viruses, fungi, and parasites. These vaccines stimulate the immune system to produce specific antibodies or cellular immune responses that can neutralize or eliminate infectious agents, preventing disease development, reducing severity, and limiting transmission.
There are various types of anti-infective vaccines, including bacterial vaccines targeting bacterial pathogens like tetanus, diphtheria, and pneumococcal infections, viral vaccines targeting viral pathogens like influenza, measles, mumps, rubella, chickenpox, hepatitis A and B, human papillomavirus (HPV), herpes zoster (shingles), and yellow fever, and fungal and parasitic vaccines targeting fungal infections like candidiasis and malaria.
The primary application of anti-infective vaccines is preventive vaccination, aiming to immunize individuals before exposure to infectious agents to prevent disease development. Vaccines play a crucial role in controlling infectious disease outbreaks by immunizing susceptible populations and limiting the spread of pathogens within communities. Travel medicine recommends anti-infective vaccines for travelers visiting regions with endemic or epidemic infectious diseases, while occupational vaccinations may be required for certain occupations. High-risk groups, such as older adults, pregnant women, immunocompromised individuals, and those with underlying medical conditions, are also recommended for vaccination.
National immunization programs and public health initiatives promote the use of anti-infective vaccines to achieve population-level immunity, reduce disease burden, and prevent outbreaks of vaccine-preventable diseases.
According to The primary goal of vaccine development would be to collect enough evidence of vaccination efficacy, immunogenicity, safety, or quality to support marketing approval requests. Vaccines are biological agents that help the body defend against infectious diseases.
What's inside a
industry report?
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
What are the Major Growth Factors for Anti-Infective Vaccines Market?
The primary drivers of the market include the prevention of infectious diseases, which stimulate the immune system to recognize and defend against specific pathogens, reducing the incidence and severity of infectious diseases. The increasing burden of infectious diseases worldwide, including bacterial, viral, fungal, and parasitic infections, is driven by factors such as population growth, urbanization, international travel, and climate change.
Technological advancements, such as the development of new adjuvants, delivery systems, and manufacturing processes, have led to the production of safer, more efficacious, and targeted vaccines. Government initiatives and vaccination programs, along with increased public health awareness, play a significant role in driving market growth. Public health awareness campaigns and disease awareness initiatives foster a culture of vaccination and promote immunization as a vital public health intervention.
Emerging infectious threats, such as pandemics, antimicrobial resistance, and bioterrorism, underscore the importance of vaccine development and preparedness. The expanded use of vaccines in high-risk populations, such as older adults, infants, pregnant women, immunocompromised individuals, and travelers to endemic regions, contributes to market growth. Globalization also facilitates the spread of infectious diseases across borders, necessitating international collaboration in vaccine development, distribution, and pandemic response.
According to Vaccine development is expensive, scientifically hard, and has a high failure rate. Successful candidates frequently face costly regulatory and production restrictions. We need to take the experiences of COVID vaccine development and accelerate our track for vaccines to solve Anti-Infective Vaccines.
What Challenges are Hampering the Growth of Anti-Infective Vaccines Market?
Complex infectious diseases like influenza viruses, HIV, and certain bacteria is known to make vaccine development challenging. High development costs can limit investment in vaccine development, especially in less profitable or niche markets. Stringent regulatory requirements can delay market entry, increase development costs, and create barriers for smaller companies or new entrants.
Safety concerns, such as public perception of vaccine safety and potential side effects, can influence vaccine uptake rates and market acceptance. Addressing safety concerns, ensuring transparency in clinical trials, and effective communication of vaccine benefits and risks are essential for building trust and confidence among healthcare professionals and the public.
Logistics and distribution challenges include inadequate storage facilities, supply chain disruptions, and logistical challenges in reaching remote or underserved populations. Vaccine hesitancy, fueled by misinformation, mistrust, cultural beliefs, and social media influence, poses a significant challenge to vaccination efforts. Addressing misinformation, promoting vaccine education, and engaging with communities are essential strategies to combat vaccine hesitancy.
Global health inequities contribute to vaccine disparities, and ensuring equitable access to vaccines, affordable pricing models, and international collaboration in distribution and financing are critical for addressing these disparities. Emerging pathogens and pandemics present unpredictable challenges for vaccine development and response.
Category-Wise Acumens
How will Dominance of Inactivated Vaccines Help Anti-Infective Vaccines Market Grow?
Inactivated vaccines is a dominant player in the anti-infective vaccines market due to their proven effectiveness in preventing various infectious diseases, safety profile, stability and storage, broad applicability, global immunity programs, manufacturing and scalability, and public confidence. They have been extensively studied and are well-established in global vaccination programs.
These vaccines contain pathogens that have been killed or inactivated, eliminating the risk of disease in vaccinated individuals, especially for vulnerable populations. They are generally more stable than live vaccines, making them suitable for distribution in resource-limited settings and regions with limited access to cold chain infrastructure.
It is type of vaccine which can be used across a wide range of age groups, making them versatile for vaccination programs targeting different populations. They are integral components of national immunization programs and global health initiatives aimed at preventing vaccine-preventable diseases.
The manufacturing process for inactivated vaccines is well-established and scalable, allowing for large-scale production to meet global demand. Public confidence in the safety and effectiveness of inactivated vaccines reinforces their dominance in the anti-infective vaccines market. However, other vaccine types, such as live attenuated vaccines, subunit vaccines, conjugate vaccines, and newer vaccine platforms like mRNA vaccines, also play crucial roles in addressing infectious diseases and expanding vaccination options.
How will Prevalence of Viral Diseases Affect the Anti-Infective Vaccines Market?
The anti-infective vaccine market addresses both bacterial and viral diseases. Viral illnesses now increasing worldwide anti-infective vaccine industry, owing to proven vaccines, frequent mutations and new threats. However, the fight against antibiotic resistance is driving significant growth in the bacterial disease segment and technological advancements and a focus on global health are expected to play an important role in its future.
Viral illnesses are increasing the development of anti-infective vaccine . This dominance arises from a three-fold advantage. To begin proven vaccines for diseases such as influenza, hepatitis, and polio have been in use for decades, producing significant and steady revenue.
Second, viruses are infamous for their fast evolution, demanding frequent updates and booster doses which drive market demand. Finally, the introduction of novel viral threats like COVID-19 emphasizes the need of viral illness vaccines, spurring additional research and development efforts in this field.
The fight against bacterial illnesses is gaining strength in the anti-infective vaccine sector. The growth in antibiotic resistance is raising fears and spurring a fresh emphasis on finding effective bacterial vaccinations. This is a wonderful sector with enormous potential.
However, it is critical to recognize the challenges. Bacterial vaccines can be more difficult to develop than viral ones. Their complicated architecture and numerous antigens make developing a broad-spectrum vaccination challenging. As a result, the present emphasis is on certain bacterial infections that cause significant mortality and morbidity rates, such as tuberculosis and pneumococcal disease.
Gain Access into Anti-Infective Vaccines Market Report Methodology
Country/Region-wise Acumens
Which Region is the Major Share Holder In the Anti-Infective Vaccines Market?
North-America contains the largest regional market for vaccines industry. North America dominated the vaccinations market (excluding covid-19 vaccines), which is projected to keep growing during the forecast period. The vaccine industry is growing due to increased investment in vaccine development by both governments and non-governmental organizations, as well as the prevalence of infectious illnesses.
North America dominates the anti-infective vaccine market due to a combination of factors. The region has a strong research and development infrastructure, with numerous renowned pharmaceutical businesses and research institutions. This turns into a solid platform for creativity.
North America has a long history of major public and private financing for vaccine development, which fuels ongoing advancement in the field. Well-developed healthcare systems and high vaccination rates in North American countries generate a strong market willing to adopt new vaccines, ensuring the region’s supremacy.
How Asia-Pacific Region is Experiencing a surge in the Anti-Infective Vaccines Market?
The Asia-Pacific area is experiencing a rise in anti-infective vaccine development. This expansion is fueled by a variety of sources. The region faces a substantial burden of infectious diseases necessitating the development of novel and improved vaccinations. Recognizing this need, many Asian countries are strategically increasing funding for vaccine development and immunization programs.
Furthermore, economic expansion in Asia-Pacific leads to increased disposable income and healthcare spending, resulting in a larger and more receptive market for new vaccinations. This combination of circumstances is leading Asia-Pacific to become the fastest-expanding market in anti-infective vaccine development.
Competitive Landscape
The anti-Infective vaccines market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.
The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the market include
- Sanofi Pasteur
- Merck & Co.,
- MedImmune LLC
- Novartis Vaccines
- Diagnostics Ltd.
- Intercell Biomedical
- MassBiologics
- Barr Labs, Inc.
- Organon Teknika Co.
- Emergent BioDefense Operations Lansing Inc.
- CSL Ltd.
- ID Biomedical Co.
- Protein Sciences Co.
- Sanofi Pasteur
- GlaxoSmithKline Biologicals
- Wyeth Pharmaceuticals, Inc.,
- Berna Biotech, Ltd.
Latest Developments
- In August 2023, Health Canada approved GSK’s Arexvy vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in people aged 60 and up. Arexvy’s approval adds to GSK’s vast portfolio of vaccines available to protect people of all ages from a variety of infectious diseases, and it is the first RSV vaccine for older adults licensed in Canada.
- In May 2023, the FDA authorized Paxlovid, an oral antiviral, for the treatment of COVID-19 in adults. Paxlovid is the fourth and first oral antiviral medication licensed by the FDA for COVID-19.
- In August 2023, Pfizer Inc. received U.S. Food and Drug Administration (FDA) approval for ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of LRTD and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals at 32–36 weeks gestational age. ABRYSVO is a unadjuvanted vaccine made up of two preF proteins chosen to optimize protection against RSV A and B strains, and it has been shown to be both safe and efficacious.
- In November 2022, Shionogi & Co, Ltd. claimed that Xocova received emergency regulatory approval from Japan’s Ministry of Health, Labour, and Welfare (MHLW) for SARS-CoV-2 infection. Xocova is a unique anti-SARS-CoV-2 treatment for COVID-19.
Report Scope
Report Attributes | Details |
---|---|
Study Period | 2021-2031 |
Growth Rate | CAGR of ~2.2% from 2024 to 2031 |
Base Year for Valuation | 2024 |
Historical Period | 2021-2023 |
Forecast Period | 2024-2031 |
Quantitative Units | Value in USD Billion |
Report Coverage | Historical and Forecast Revenue Forecast, Historical and Forecast Volume, Growth Factors, Trends, Competitive Landscape, Key Players, Segmentation Analysis |
Segments Covered |
|
Regions Covered |
|
Key Players | Merck & Co.,, MedImmune LLC, Novartis Vaccines, Diagnostics Ltd., Intercell Biomedical, MassBiologics, Barr Labs, Inc., Organon Teknika Co., Emergent BioDefense Operations Lansing Inc., CSL Ltd., ID Biomedical Co., Protein Sciences Co., Sanofi Pasteur, GlaxoSmithKline Biologicals, Wyeth Pharmaceuticals, Inc.,, Berna Biotech, Ltd. |
Customization | Report customization along with purchase available upon request |
Anti-Infective Vaccines Market, By Category
Technology
- Conjugate Vaccines
- Recombinant Vaccines
- Inactivated and Subunit Vaccines
- Live Attenuated Vaccines
- Toxoid Vaccines
- Viral Vector Vaccines
- m-RNA Vaccines
- Others
Type
- Inactivated Vaccines
- Conjugate Vaccines
- Monovalent Vaccines
- Mulitvalent Vaccines
Application
- Bacterial Diseases
- Viral Diseases
Route of Administration
- Intramuscular & Subcutaneous
- Oral
- Others
End-User
- Pediatric Vaccine
- Adult Vaccine
Region
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Research Methodology of Market Research
To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .
Reasons to Purchase this Report
• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post sales analyst support
Customization of the Report
• In case of any please connect with our sales team, who will ensure that your requirements are met.